CURRICULUM VITAE

Name:	Paolo Tosco
Place and date of birth:	Turin, 27 November 1974
Lab address:	Dipartimento di Scienza e Tecnologia del Farmaco Via Pietro Giuria, 9 10125 Torino Tel. +39 011 6707680 Fax +39 011 6707687
E-mail:	paolo.tosco@unito.it

Paolo Tosco was born in Turin on November 27th, 1974. In 1999 he got the master degree in "Chimica e Tecnologia Farmaceutiche" from the University of Turin, where after the civil service he undertook PhD studies in Drug Chemistry ("Chimica del Farmaco"). After a two-year post-doctoral fellowship, at the end of 2004 he became Assistant Professor in Medicinal Chemistry at the Drug Science and Technology Department ("Dipartimento di Scienza e Tecnologia del Farmaco") in Turin. Since 1998 he has worked in the research group headed by Professor Alberto Gasco, focussing his activity on the synthesis of NO-donor molecular hybrids endowed with H_3-antagonistic properties. During 2002 and 2003 he spent two periods of study at the Medicinal Chemistry Department ("Dipartimento di Chimica Farmaceutica") of "Federico II" University in Naples under the supervision of Professor Paolo Grieco, where he performed solid-phase peptide synthesis. During 2005 he spent six months by the Medicinal Chemistry Department ("Laboratoire de Chimie Therapeutique") at the University of Genève under the supervision of Professor Pierre-Alain Carrupt, where he acquired skills in computational chemistry and molecular modelling. Since then, his research has been dedicated almost exclusively to these topics. In summer 2006 he spent one month in Minneapolis working in Prof. Portoghese's Medicinal Chemistry group. In spring 2008 he spent three months by the Medicinal Chemistry Department at the University of Copenhagen studying nicotinic ligands specific for the $\alpha_4\beta_2$ subtype by a mixed ligand-based/structure-based approach relying on 3D-QSAR and homology modeling. His research interests focus on the rationalisation of the biological activity profile in a series of compounds by molecular simulation and chemometric analysis. In particular, he has gained experience with structure-based modelling on cyclooxygenase inhibitors and in the establishment of QSAR models on different classes of antioxidants.